A Phase I study of AZD3152 in healthy Chinese adult participants

Study identifier:D7000C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of AZD3152 in Healthy Chinese Adults

Medical condition

COVID-19

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Placebo

Sex

All

Estimated Enrollment

48

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Mar 2024
Estimated Primary Completion Date: 30 Apr 2024
Estimated Study Completion Date: 01 Apr 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria